Formula Growth’s Faeth Therapeutics FTH Stock Holding History

Formula Growth’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-5,000	Closed	-$976K	–	159
2021 Q2	$976K	Buy	5,000 +2,186	+78%	+$540K	0.13%	134
2021 Q1	$818K	Buy	+2,814	New	+$942K	0.12%	149

Other funds holding FTH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $74.2B AUM 21.09% 1-Year Est. Return

Formula Growth's FTH Position: Q3 2021 in Review

Formula Growth sold out of Faeth Therapeutics (FTH) in Q3 2021, closing a stake of 5,000 shares — an estimated $976K sold.

Formula Growth first reported a position in FTH in Q1 2021 and held it in 2 quarters. The position peaked at $976K in Q2 2021. 42 funds tracked by Wall St. Rank hold FTH as of Q3 2021.

Formula Growth reported no remaining Faeth Therapeutics position as of Q3 2021 after selling out during the quarter.
Formula Growth sold 5,000 Faeth Therapeutics shares in Q3 2021, an estimated $976K.
Formula Growth first reported a position in Faeth Therapeutics in Q1 2021 and held it in 2 quarters.
Formula Growth's Faeth Therapeutics position peaked at $976K in Q2 2021.
42 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q3 2021.

Based on Formula Growth's 13F filing for Q3 2021, filed 12 Nov 2021.